XNAS · Biotechnology
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$117.75-0.62%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
60/100
Positive
Score components
TickerWhale View
Kymera Therapeutics scores 60 out of 100 overall, which we rate positive. Technical is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Risk
What to watch
- Valuation
Quality & growth
30%53Moderate
- Revenue growth 134.8%
- EPS growth n/a
Valuation
25%40Weak
- P/E -38.6
- EV/Sales 108.9
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#54 / 139sector rank by TickerWhale Score
TickerWhale Score 60 vs sector average 55.1 (+4.9)
Revenue growth (industry)Top 16%
Return on equity (industry)Top 49%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
87/100Strong vs universe
Ranks 87th of 100 covered names on our technical composite — the composite itself scores 69/100 · 25% of the TickerWhale Score
Classic chart indicators
Neutral
2 buy · 2 sell · 4 neutral of 8 votes
TickerWhale rates KYMR's technical setup strong — 87th percentile of the covered universe. Classic chart indicators lean neutral — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
8 / 9constructive
- vs 200-day+28.9%
- vs 50-day+2.9%
Momentum
Mixed
- RSI (14)53 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength11· weak trend
- MACD (12,26,9)sell(histogram -0.477)
How the classic verdict is reached
Moving averages (9) agree on buy — 8 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 1 buy · 2 sell · 4 neutral.
Result — 2 buy vs 2 sell of 8 votes = Neutral. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)-38.6 · TTM loss
- P/S (TTM)110.1
- P/B7.7
- EV/EBITDA—
- EV/Sales108.9
- PEG—
Profitability & returns
- Gross margin—
- Net margin-285.3%
- ROE-19.7%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)134.8%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $11.6B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KYMRCurrentKymera Therapeutics | 60 | 69 | -38.6 | — | 7.7 | 108.9 | $117.75 | -0.62% | +134.8% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.